Dural Sinus Stenting of Low Grade Dural Arteriovenous Fistulae (DAVF) for Pulsatile Tinnitus Treatment

Exclusion Criteria

• •DAVF classification of IIb or more according to Cognard's classification.
• •DAVF with severe sinus stenosis or occlusion judged as nor eligible for sinus stenting.
• •DAVF showing evidence of recent (inferior to 3 months) thrombophlebitis at the site of fistulous dural sinus.
• •Patient with DAVF previously treated with surgery or radiotherapy.
• •Patient with multiple DAVF
• •Controlateral sinus aplasia or occlusion
• •Patient presenting contra-indication to the use of LEA according to the instructions For Use.
• •Patient participating in another clinical study evaluating another medical device,
• •Any condition or any situation that would prohibit the patient from coming to the investigational center for the follow-up as recommended by the study protocol at 6 months.
• •Patient with any known allergy to heparin, acetylsalicylic acid, Coumadin , Warfarin or other antiplatelet medications
• •Patient has undergone a surgery including endovascular procedures in the last 30 days prior to the study procedure.
• •Patient has had an Intracranial hemorrhage and/or subarachnoid hemorrhage in the past 30 days prior to the study procedure
• •Known serious sensitivity to radiographic contrast agents.
• •Known sensitivity to nickel, titanium metals, or their alloys
• •Known renal failure as defined by a serum creatinine \> 2.5 mg/dl (or 220 μmol/l) or glomerular filtration rate (GFR) \< 30.
• •Patient who has a contraindication to MRI or angiography for whatever reason
• •Women who are pregnant, lactating, or who are planning to become pregnant during the anticipated study period
• •Patient unable to understand the nature, risks, significance and implications of the clinical investigation or unwilling to provide written informed consent
• •Patient under legal protection